Cargando…

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes

Omicron is the evolutionarily most distinct SARS-CoV-2 variant of concern (VOC) to date. We report that Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted in strong neutralizing activity against Omicron BA.1, BA.2 and previous SARS-CoV-2 VOCs, but not against the Omicron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quandt, Jasmin, Muik, Alexander, Salisch, Nadine, Lui, Bonny Gaby, Lutz, Sebastian, Krüger, Kimberly, Wallisch, Ann-Kathrin, Adams-Quack, Petra, Bacher, Maren, Finlayson, Andrew, Ozhelvaci, Orkun, Vogler, Isabel, Grikscheit, Katharina, Hoehl, Sebastian, Goetsch, Udo, Ciesek, Sandra, Türeci, Özlem, Sahin, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162083/ https://www.ncbi.nlm.nih.gov/pubmed/35653438 http://dx.doi.org/10.1126/sciimmunol.abq2427

Ejemplares similares

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
por: Wilhelm, Alexander, et al.
Publicado: (2022)

Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination
por: Delbrück, Marla, et al.
Publicado: (2022)

Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group
por: Hoehl, Sebastian, et al.
Publicado: (2020)

Is Olfactory Testing a Useful Diagnostic Tool to Identify SARS-CoV-2 Infections Early? A Cross-Sectional and Longitudinal Analysis
por: Graf, Christiana, et al.
Publicado: (2023)

Targeting the tumor vasculature with engineered cystine-knot miniproteins
por: Lui, Bonny Gaby, et al.
Publicado: (2020)

Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
por: Hoehl, Sebastian, et al.
Publicado: (2023)

Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination
por: Grikscheit, Katharina, et al.
Publicado: (2022)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach
por: Layer, Emily, et al.
Publicado: (2022)

A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated
por: Hoehl, Sebastian, et al.
Publicado: (2021)

Die Virologie von SARS-CoV-2
por: Hoehl, S., et al.
Publicado: (2020)

Die Virologie von SARS-CoV-2
por: Hoehl, S., et al.
Publicado: (2020)

Die Virologie von SARS-CoV-2
por: Hoehl, S., et al.
Publicado: (2020)

Thirty years of CMV seroprevalence—a longitudinal analysis in a German university hospital
por: Hoehl, Sebastian, et al.
Publicado: (2020)

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2021)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
por: Pather, Shanti, et al.
Publicado: (2023)

SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines
por: Pather, Shanti, et al.
Publicado: (2023)

Reply to Fabbris et al. A Viable Alternative. Comment on “Kohmer et al. Self-Collected Samples to Detect SARS-CoV-2: Direct Comparison of Saliva, Tongue Swab, Nasal Swab, Chewed Cotton Pads and Gargle Lavage. J. Clin. Med. 2021, 10, 5751”
por: Hoehl, Sebastian, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs)
por: Kohmer, Niko, et al.
Publicado: (2021)

Breakthrough in the high-pressure structures of Ba based on full exploitation of aperiodic symmetry
por: Boldyreva, Elena V.
Publicado: (2017)

Novel multiple swab method enables high efficiency in SARS‐CoV‐2 screenings without loss of sensitivity for screening of a complete population
por: Schmidt, Michael, et al.
Publicado: (2020)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Early computational detection of potential high-risk SARS-CoV-2 variants
por: Beguir, Karim, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
por: Widera, Marek, et al.
Publicado: (2021)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?
por: Toptan, Tuna, et al.
Publicado: (2021)

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
por: McLean, Gary, et al.
Publicado: (2022)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
por: Li, Jingxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n95p4infa59uad6r0nito5v02s